Canada
· Delayed Price · Currency is CAD Aptose Biosciences Statistics
Total Valuation
Aptose Biosciences has a market cap or net worth of CAD 19.55 million. The enterprise value is 8.16 million.
| Market Cap | 19.55M |
| Enterprise Value | 8.16M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aptose Biosciences has 21.96 million shares outstanding. The number of shares has increased by 37.99% in one year.
| Shares Outstanding | 21.96M |
| Shares Change (YoY) | +37.99% |
| Shares Change (QoQ) | +67.36% |
| Owned by Insiders (%) | 0.47% |
| Owned by Institutions (%) | 4.64% |
| Float | 18.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 75.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.13 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.13 |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 670.80.
| Current Ratio | 0.97 |
| Quick Ratio | 0.77 |
| Debt / Equity | 670.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -361.05% and return on invested capital (ROIC) is -212.31%.
| Return on Equity (ROE) | -361.05% |
| Return on Assets (ROA) | -115.15% |
| Return on Capital (ROIC) | -212.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.77M |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.44% in the last 52 weeks. The beta is 1.47, so Aptose Biosciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -84.44% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 2.42 |
| Relative Strength Index (RSI) | 32.87 |
| Average Volume (20 Days) | 9,661 |
Short Selling Information
The latest short interest is 6,975, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 6,975 |
| Short Previous Month | 10,084 |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -65.02M |
| Pretax Income | -63.88M |
| Net Income | -63.88M |
| EBITDA | -64.92M |
| EBIT | -65.02M |
| Earnings Per Share (EPS) | -7.52 |
Balance Sheet
The company has 12.63 million in cash and 1.24 million in debt, giving a net cash position of 11.39 million or 0.52 per share.
| Cash & Cash Equivalents | 12.63M |
| Total Debt | 1.24M |
| Net Cash | 11.39M |
| Net Cash Per Share | 0.52 |
| Equity (Book Value) | 185,514 |
| Book Value Per Share | 0.01 |
| Working Capital | -430,610 |
Cash Flow
In the last 12 months, operating cash flow was -61.00 million and capital expenditures -39,269, giving a free cash flow of -61.04 million.
| Operating Cash Flow | -61.00M |
| Capital Expenditures | -39,269 |
| Free Cash Flow | -61.04M |
| FCF Per Share | -2.78 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aptose Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.99% |
| Shareholder Yield | -37.99% |
| Earnings Yield | -844.80% |
| FCF Yield | -312.27% |
Stock Splits
The last stock split was on June 6, 2023. It was a reverse split with a ratio of 0.0666667.
| Last Split Date | Jun 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0666667 |